Novo Nordisk’s chief executive is preparing for a showdown next week with progressive firebrand Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into ...
The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices – Includes Caremark, Express Scripts, ...
Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have ...
The Federal Trade Commission (FTC) filed a lawsuit Friday against three major prescription drug benefit managers (PBMs) and ...
Among other things, NCPA is urging CMS to require Part D plans/PBMs to notify pharmacies or their contracting entities about the pharmacies’ network status for the upcoming plan year ...
Eli Lilly (NYSE:LLY) on Thursday announced that its QWINT-1 and QWINT-3 Phase 3 clinical trials for once-weekly insulin efsitora alfa reached the primary endpoints against daily basal insulins ...
In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first time In a ...
(RTTNews) - Eli Lilly and Company (LLY) Thursday announced positive topline results from the QWINT-1 and QWINT-3 phase 3 studies evaluating once weekly basal insulin efsitora alfa in adults with ...
Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback